文献速递胸部肿瘤放疗

不可手术非小细胞肺癌的根治性加速放疗:两种剂量分割方案的5年回顾性分析

Radical accelerated radiotherapy for non-small cell lung cancer (NSCLC): A 5-year retrospective review of two dose fractionation schedules.
PubMed 文献 · Radiother Oncol · 2019-09-25

中位总生存22.5个月,2年生存率48%,多因素分析显示组织学、分期、体能状态、化疗和放疗反应为独立预后因素。

要点

  • CHART与55 Gy/20次加速分割方案在不可手术NSCLC中疗效相似。
  • 中位总生存22.5个月,2年生存率48%,90天死亡率6.5%。
  • 组织学、分期、PS、化疗及放疗反应为独立生存预测因素。

核心结论

  • 本中心CHART与hypofractionated accelerated radiotherapy产生相似的治疗结局。

主要发现

  • 43%接受CHART,57%接受hypofractionated radiotherapy;中位年龄71岁,56%为男性,95%行PET分期,53% WHO PS 0-1。
  • 分期I、II、III、IV分别占30%、14%、50%、6%;38%接受诱导化疗;99%完成处方放疗。
  • 总体缓解率50%,90天死亡率6.5%;中位无病生存19个月,50%局部复发;中位总生存22.5个月,2年生存率48%。
  • 多因素分析显示组织学、分期、体能状态、化疗和放疗反应为独立生存预测因素,两种放疗方案间无显著差异。

临床怎么用

  • 对于不适合SABR的不可手术NSCLC,CHART与55 Gy/20次加速分割均可作为推荐方案选择。
  • 需结合组织学、分期、PS、是否化疗及放疗反应进行个体化预后评估。

局限性

  • 单中心回顾性设计,可能存在选择偏倚;未报告两组间具体比较的P值或置信区间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Numerous fractionation regimes are used for inoperable NSCLC patients not suitable for stereotactic ablative radiotherapy. Continuous hyperfractionated accelerated radiotherapy (CHART, 54 Gy, 36 fractions over 12 days) and hypofractionated accelerated radiotherapy (55 Gy, 20 fractions over 4 weeks) are recommended UK schedules. In this single-centre retrospective analysis, we compare both fractionation schemes for patients treated at our institution from 2010 to 15. MATERIALS AND METHODS: Clinical demographic, tumour and survival data were collected alongside radiotherapy dosimetric data from the Varian Eclipse Scripting application programming interface. Differences were assessed using independent samples t-tests. Multivariate survival analysis was performed using Cox regression. RESULTS: We identified 563 eligible patients; 43% received CHART and 57% hypofractionated radiotherapy. Median age was 71 years, 56% were male, 95% PET staged with 53% WHO performance status 0-1. 30%, 14%, 50% and 6% were stage I, II, III and IV, respectively. 38% of patients underwent induction chemotherapy. 99% completed their prescribed radiotherapy treatment. Overall response rate was 50% with a 6.5% 90-day mortality rate. Median disease-free survival was 19 months, 50% recurred locally. Median overall survival was 22.5 months with 48% alive at 2 years. Multivariate analysis identified histology, stage, performance status, chemotherapy and radiotherapy response as independent predictors of survival; no significant differences between radiotherapy regimes were observed. CONCLUSION: In our centre, CHART and hypofractionated accelerated radiotherapy produce similar outcomes. Dose escalation studies are in progress to develop these schedules to match outcomes reported in concurrent chemo-radiation studies.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Robinson SD, Tahir BA, Absalom KAR, et al. Radical accelerated radiotherapy for non-small cell lung cancer (NSCLC): A 5-year retrospective review of two dose fractionation schedules. Radiother Oncol. 2019. PMID: 31563408. doi:10.1016/j.radonc.2019.08.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。